Interestingly, the WGD frequency of CHEK2 pBCs was in between TP53 wild-type and mutant pBCs (35.7% vs. 19.3% and 63.3%, respectively, P = 0.17 and P = 0.049), which fits the moderate BC risk associated with CHEK2 c.1100delC. This evidence concerns the gene CHEK2 and breast cancer.